	Application No.	Applicant(s)
Notice of Allowability	09/830,354	IKONOMIDOU, HRISSANTHI
	Examiner	Art Unit
	Anand U Desai, Ph.D.	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>March 4, 2004</u> .		
2. The allowed claim(s) is/are <u>1-3,5,6,34 and 39-41</u> .		
3. The drawings filed on are accepted by the Examiner.		
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)</li></ul>		
International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
		-
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5.  Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date		
4. Examiner's Comment Regarding Requirement for Deposit		ent of Reasons for Allowance
of Biological Material	9.  Other	
•	i	

Application/Control Number: 09/830,354

Page 2

Art Unit: 1653

#### **DETAILED ACTION**

## **Priority**

1. Acknowledgment is made of applicant's claim for priority under 35

U.S.C. 119(a)-(d). The priority date is October 28, 1998.

This office action is in response to Amendment filed March 4, 2004. Claims 22 and 23 were withdrawn from further consideration by the Examiner because these claims are drawn to non-elected inventions. New claims 38-41 have been added. Claims 38 is directed to a method that was previously restricted and is withdrawn. Claims 8-33, 35-38 are withdrawn from further consideration. Claims 1-7, and 34, 39-41 are currently pending and are under examination.

### **EXAMINER'S AMENDMENT**

2. An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Csaba Henter on April 23, 2004.

# **Examiner's Amendment to the Claims:**

- 4. (cancelled)
- 7. (cancelled)
- 9. (withdrawn)
- 16. (withdrawn)
- 23. (withdrawn)

Application/Control Number: 09/830,354

Art Unit: 1653

38. (withdrawn)

40. (amended) A method according to claim 1, wherein the inhibitor is amino alkanoic acid, amino-phenyl-acetic acid, amino- or desamino- 2,3-benzodiazepine, 2,3-benzodiazepin-4-one, alkoxy-phenyl-benzodiazepine, acetyl-aminophenyl-dihydro-methyl-dioxolo-benzodiazepine, benzothiadiazine, decahydroisoquinoline, β-carboline-3-carboxylic acid, fused cycloalkylquinoxalinedione, 4-hydroxypyrrolone, 4-hydroxy-pyrrolo-pyridazinone, indeno-pyrazine-carboxylic acid, indeno-pyrazinone, imidazoloquinoxalinone, isatine, isatinoxime, oxadiazole, phenyl-azolophthalazine, phenylpyridazino-indole-l,4-dione, quinoline, quinolone, quinolone, nitroquinolone, quinoxaline, quinoxalinedione, quinazolinone, 4-hydroxy-pyrrolo-pyridazinone, or phenyl-azolophthalazine.

## Allowable Subject Matter

3. Claims 1-3, 5, 6, 34, 39, 40, and 41 are allowable.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statements of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anand U Desai, Ph.D. whose telephone number is (571) 272-0947. The examiner can normally be reached on Monday - Friday 9:00 a.m. - 5:30 p.m..

Application/Control Number: 09/830,354

Art Unit: 1653

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (517) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

\*\*\*

April 23, 2004

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

How Cahare Calson Rus.